Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...

Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...

Sanofi's amlitelimab confirms its potential in atopic dermatitis: Paris Saturday, January 24, 2026, 10:00 Hrs [IST] Following the positive COAST 1 (clinical study identifier: NCT0 ...

Learn how to enable and use iOS 26's Camera Remote feature to take iPhone photos and videos by pressing your AirPods instead ...

Another Chinese robotics player, Unitree, is pushing the limits of humanoid robotics. On January ...

The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...

CES 2026 shifted robots from tech demos to actual workers. LG's CLOiD folds laundry (slowly), Boston Dynamics' Atlas lifted 110 pounds for factories, and Roborock's Rover finally climbed stairs.

2026 is the EU’s digital “set-up” year: a time to simplify rules, set priorities, and brace for transatlantic spillovers as major legislative initiatives race toward 2027. View on euronews ...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...

ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, ...

Laughing Water Capital reported a 3.9% annual return, emphasizing fundamental growth in core holdings despite a market ...